

1 **Differences in sensory nerve block between**  
2 **levobupivacaine and bupivacaine at low concentrations**  
3 **in humans and animals**

4

5 Short title: Selective block of nociceptive stimuli by levobupivacaine

6

7 Akiyuki Sakamoto<sup>1,2\*</sup>, Satoshi Tanaka<sup>1</sup>, Takashi Ishida<sup>1</sup> Mikito Kawamata<sup>1</sup>

8

9 <sup>1</sup> Department of Anesthesiology and Resusitology, Shinshu University School of  
10 Medicine, Matsumoto 390-8621, Japan.

11 <sup>2</sup> Shinonoi General Hospital the Department of Anesthesiology, Nagano 388-8004,  
12 Japan.

13

14 \* Corresponding author

15 E-mail: [akiyuki@shinonoi-hp.jp](mailto:akiyuki@shinonoi-hp.jp) (AS)

16

17 **Author contributions**

18 Data curation: T Ishida; Formal analysis: T Ishida, Funding acquisition: A Sakamoto;

19 Investigation: A Sakamoto, S Tanaka; Methodology: S Tanaka; Project administration:

20 A Sakamoto; Resources: A Sakamoto; Software: T Ishida; Validation: S Tanaka;

21 Visualization: A Sakamoto; Writing – original draft: A Sakamoto; Writing – review &

22 editing: S Tanaka, T Ishida, M Kawamata

## 23 **Abstract**

24 Physiochemical properties of levobupivacaine and bupivacaine are identical, but  
25 pharmacokinetic and pharmacodynamics properties differ due to stereoselective  
26 interactions at the molecular sites of action. An evaluation of nerve block characteristics  
27 essential for optimal clinical application. This study compared the sensory blocking  
28 characteristics of levobupivacaine to bupivacaine in humans and model animals.  
29 Levobupivacaine and bupivacaine were compared for sensory block efficacy using a  
30 randomized, double-blinded, crossover study design. Eighteen healthy volunteers were  
31 randomized to receive levobupivacaine or bupivacaine by subcutaneous injection into the  
32 forearm, followed by the other drug 1 week later with injection order counterbalanced  
33 across subjects. Tactile detection and mechanical pain thresholds were determined using  
34 von Frey hairs and thermal pain threshold using a thermal stimulator. Effects of  
35 levobupivacaine and bupivacaine, on the spiking activity of spinal dorsal horn (SDH)  
36 neurons evoked by innocuous or noxious stimuli were also compared in anesthetized  
37 Sprague–Dawley rats by in vivo extracellular recordings. There were no significant  
38 differences in mechanical and thermal pain thresholds following levobupivacaine or  
39 bupivacaine injection at 0.025%, 0.0625%, and 0.125%. There was also no significant  
40 difference in tactile detection threshold following levobupivacaine or bupivacaine  
41 injection at 0.125%. However, tactile detection threshold was significantly higher after  
42 administration of bupivacaine at 0.025% and 0.0625% compared to equivalent doses of  
43 levobupivacaine. Subcutaneous injection of bupivacaine at 0.05% also induced  
44 significantly greater inhibition of SDH neuron spiking activity evoked by innocuous  
45 stimuli compared to an equivalent dose of levobupivacaine, while there was no significant

46 difference in suppression of spiking activity evoked by noxious stimuli. Low-dose  
47 bupivacaine induces greater suppression tactile sensation than low-dose levobupivacaine.  
48 Thus, low-dose levobupivacaine demonstrates relatively greater blocking selectivity for  
49 noxious over innocuous stimuli compared to low-dose bupivacaine. Levobupivacaine  
50 may be advantageous for applications where pain must be suppressed but non-nociceptive  
51 sensations maintained.

52

## 53 **Introduction**

54 Bupivacaine is a long-acting local anesthetic that has been used clinically for several  
55 decades as a racemic mixture (50:50) of dextrorotatory R-(+)- and levorotatory S-(-)-  
56 isomers. However, the R-(+)-isomer may contribute disproportionately to adverse effects  
57 on the nervous and cardiovascular systems than the S-(-)-isomer [1-5]. Therefore,  
58 levobupivacaine, the pure S-(-)-isomer of bupivacaine, has been introduced into clinical  
59 practice as a safer alternative. Although the physiochemical properties of levobupivacaine  
60 and bupivacaine are identical, they differ in pharmacokinetic and pharmacodynamics  
61 properties due to stereoselective interactions at molecular targets [4-6].

62 Local anesthetics at sufficient concentrations can prevent impulse transmission by  
63 all types of peripheral nerves, resulting in motor blockade and sensory blockade for both  
64 noxious and innocuous stimuli. Complete block of motor and sensory transmission is  
65 generally beneficial during surgery, while nociceptive-specific block without motor  
66 paralysis or loss of innocuous sensation is often desirable in the post-operative period to  
67 facilitate earlier mobilization. The motor-blocking potency of levobupivacaine is lower  
68 than that of bupivacaine at the same concentration and amount when administered by  
69 intrathecal and epidural routes [5, 7-10]. Recently, Uta and colleagues reported that  
70 levobupivacaine also potently inhibits A $\delta$ - and C-fiber transmission but requires a  
71 higher dose to suppress A $\beta$  fiber transmission compared to bupivacaine as evidenced by  
72 whole cell patch-clamp recordings from rat spinal dorsal horn (SDH) neurons [11].  
73 Nerve fibers of the A $\beta$ -type transmit tactile and pressure sensations, whereas A $\delta$ - and C-  
74 fibers transmit nociception from noxious stimuli [12]. Therefore, we hypothesized that  
75 levobupivacaine would produce greater nociceptive-specific block than bupivacaine, a

76 property especially useful in the outpatient surgery setting. However, these differential  
77 blocking properties have not been confirmed in vivo.

78 It is of great importance to characterize the sensory block characteristics of bupivacaine  
79 and levobupivacaine for optimal clinical applications. The purpose of the present study  
80 was to compare the relative selectivity of racemic bupivacaine to levobupivacaine for  
81 pain sensation and tactile sensation block by measuring sensory thresholds in human  
82 volunteers and the spiking activity of SDH neurons in response to noxious and innocuous  
83 cutaneous stimuli by in vivo single unit extracellular recordings in anesthetized rats.

84

## 85 **Materials and methods**

86 This study consists of two parts. In Experiment (1), we compared the effects of  
87 levobupivacaine to bupivacaine on the tactile detection threshold and both mechanical  
88 and thermal pain sensation thresholds following subcutaneous administration in healthy  
89 human volunteers. In Experiment (2), the effects of subcutaneous levobupivacaine and  
90 bupivacaine administration were compared for suppression of SDH neuron activity  
91 evoked by innocuous and noxious stimuli in anesthetized rats.

92

### 93 **Experiment (1): Effects of subcutaneous levobupivacaine and** 94 **bupivacaine on human sensory thresholds**

#### 95 **Subjects**

96 Experiment (1) was conducted in accordance with the principles outlined in the  
97 Declaration of Helsinki and the ethical guidelines for pain research in humans of the  
98 International Association for Study of Pain. All protocols were approved by the Ethics  
99 Committee of Shinshu University School of Medicine, Matsumoto, Japan (document  
100 number: 3252) on October 8, 2015. Experiment (1) was also registered with the  
101 University Hospital Medical Information Network in Japan (number UMIN000019307)  
102 on October 10, 2015. Recruitment for the study ran from October 13, 2015 to February  
103 15, 2018 and conducted from October 18, 2015 to March 3, 2018 at Shinshu University  
104 Hospital, Matsumoto, Japan. Written informed consent was obtained from each subject  
105 before testing. A randomized, double-blinded, crossover design was implemented to  
106 compare different subcutaneous doses of levobupivacaine and bupivacaine without bias.

107 Eighteen volunteers (15 male and 3 female) aged 23–46 years old were recruited at  
108 Shinshu University School of Medicine. Inclusion criteria were 20 years of age or older  
109 and willing to provide informed consent. Exclusion criteria were analgesic allergies, drug  
110 or alcohol abuse, diabetes, neuromuscular diseases, chronic pain, and daily use of  
111 analgesics.

112

### 113 **Study protocol**

114 A CONSORT diagram of study enrolment is presented in Fig 1. The 18 volunteers were  
115 randomly assigned to receive either levobupivacaine in the first period followed by  
116 bupivacaine in the second period or bupivacaine in the first period followed by  
117 levobupivacaine in the second period at a 1:1 ratio (crossover design). Volunteers were  
118 randomized to the levobupivacaine-first or bupivacaine-first group using the random  
119 generation function in Microsoft Excel with a permuted random block size of 6. Subjects  
120 were further randomly divided into three dose groups receiving 0.125%, 0.0625%, or  
121 0.025% injections. These groups were administered the same dose of the other local  
122 anesthetic after a 1-week washout period. The commercial 0.5% bupivacaine preparation  
123 Marcaine® (AstraZeneca KK, Osaka, Japan) and the 0.5% levobupivacaine preparation  
124 Popsaine® (Maruishi, Tokyo, Japan) were diluted in sterile normal saline on the test day  
125 to yielded the 0.125%, 0.0625%, or 0.025% solutions for subcutaneous injection. Freshly  
126 prepared solutions were injected into the anterior aspect of the left forearm at a volume  
127 of 3 mL using a 25-gage needle under ultrasound guidance (S-Nerve™, SonoSite Japan  
128 KK., Tokyo, Japan). The tactile detection threshold (TDT) and mechanical pain threshold  
129 (MPT) were determined at the center of the injected area by applying von Frey (vF) hairs  
130 of increasing stiffness (force). The TDT was measured from a baseline force of 0.16 g

131 and MPT from a baseline of 6 g. Participants were instructed to announce when touch  
132 was first detected (TDT) and when the stimulus became painful (MPT). Each threshold  
133 was measured three times at intervals of 10 s, and the median value was recorded for  
134 analyses. The thermal pain threshold (TPT) was measured using a thermal stimulator  
135 (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan). The thermode, a Peltier  
136 element covered by a ceramic contact plate (6 mm × 6 mm), was heated at a rate of 1.0°C/s  
137 from a baseline temperature of 32°C to a maximum of 47°C to prevent injury. Participants  
138 were instructed to notify when thermal pain sensation was detected. Evaluators of these  
139 sensory thresholds were blinded to the anesthetic administered. Measurements were  
140 performed before injection and 5, 15, 30, 45, and 60 min after injection in a quiet room  
141 with controlled ambient temperature (22°C–24°C) (Fig 2).

142

143 **Fig 1. CONSORT diagram illustrating the flow of participants through each phase**  
144 **of the randomized crossover trial**

145 **Fig 2. Schematic diagram of Experiment (1) in humans.**

146 Tactile and mechanical pain thresholds were determined using von Frey (vF) hairs applied  
147 for 5 s, while thermal pain threshold was measured using a thermal stimulator  
148 (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan) heated at 1°C/min from  
149 32°C to a maximum of 47°C. All thresholds were measured at baseline and again at the  
150 same site and times following subcutaneous injection of local anesthetic (LA).

151

152 To control for possible carryover effects from one injection to the next, the total  
153 scores for each period were compared between two sequence groups using an independent  
154 samples t-test. Furthermore, the effect of each period was examined by comparing the



155 thresholds in the first period with the thresholds in the second period using paired-sample  
156 t-tests [13].

157

## 158 **Experiment (2): Effects of subcutaneous levobupivacaine and** 159 **bupivacaine on spinal dorsal horn transmission in anesthetized** 160 **rats**

161 All animal care and study protocols were approved by the Shinshu University School of  
162 Medicine Animal Care and Use Committee (no. 021118) and conducted in accordance  
163 with the guidelines of the National Institutes of Health. Seven-week-old male Sprague–  
164 Dawley rats weighing 180–220 g were housed under controlled temperature (22–23°C),  
165 humidity 40%–60%, and light/dark cycle (12-hour/12-hour) with ad libitum access to  
166 food and water.

167 Prior to neuronal recordings, rats were anesthetized with 3% sevoflurane in oxygen.  
168 A middle vertical incision was made over the dorsum and the underlying paraspinous  
169 musculature was detached from the spinous processes and dorsal aspects of vertebrae  
170 from T10 to L3. Dorsal laminectomies were performed across T12–L1 to expose the  
171 lumbar intumescence. The rat was then placed into a stereotaxic frame (Model ST-7,  
172 Narishige, Tokyo, Japan) and secured using vertebral clamps and ear bars. After removing  
173 the dura, the surface of the spinal cord was irrigated at 10 mL/min with Krebs's solution  
174 (in mM, NaCl, 117; KCl, 3.6; CaCl<sub>2</sub>, 1.2; NaH<sub>2</sub>PO<sub>4</sub>, 1.2; glucose, 11; NaHCO<sub>3</sub>, 25 mM)  
175 aerated with 95% O<sub>2</sub>–5% CO<sub>2</sub>. Body temperature was maintained at 36°C–38°C using an  
176 infrared heat lamp and thermo-controlled heat pad based on feedback from a rectal

177 thermometer.

178 Extracellular recordings from single neurons were acquired using a tungsten  
179 electrode (10–12 M $\Omega$ ; FHC Inc., Brunswick, ME) inserted in the deep dorsal horn of the  
180 lumbar spinal cord. We identified neurons (single units) according to the mechanical  
181 receptive fields (RF) of the hindpaw. Extracellular action potentials were amplified  
182 ( $\times 20000$ – $50000$ ), band-pass filtered between 300–3000 Hz, digitized (CED 1401;  
183 Cambridge Electronic Design, Cambridge, UK), and stored on an IBM-AT personal  
184 computer (Think Pad; IBM Japan, Tokyo). Spike trains were analyzed using Spike 2  
185 (Cambridge Electronic Design).

186 Neurons that responded to both an innocuous stimulus (light touch with a camel-hair  
187 brush) and a noxious stimulus (pinch force of 250 g/mm<sup>2</sup> using an arterial clip) were  
188 classified as wide-dynamic-range (WDR), those responsive to noxious but not non-  
189 noxious stimuli as high-threshold, and those responsive to low- but not high-intensity  
190 stimulation as low-threshold (LT). Only WDR and LT neurons were examined in this  
191 study. Consistent with previous reports, all WDR neurons included in the analysis  
192 responded to greater stimulus intensities with a graded increase in spike frequency [14],  
193 while LT neurons responded only to light mechanical (innocuous) stimuli from a 10 g or  
194 lighter vF hair [15]. Therefore, the pinch stimulus was used throughout as a strong  
195 noxious stimulus and a 10 g vF hair as a weak noxious stimulus. The responses of  
196 individual WDR neurons to stimulation by 4 g and 10 g vF hairs, a brush, and pinch at  
197 the center of the RF were recorded in order. Similarly, the responses of LT neurons to  
198 stimulation by a 4 g vF hair and a brush at the center of the RF were recorded in order.  
199 For measurement of levobupivacaine and bupivacaine effects on these responses, rats  
200 were randomly allocated to receive a 500-microL subcutaneous injection of 0.05%

201 levobupivacaine, 0.05% bupivacaine, or equal-volume saline using a 30-gage needle  
202 targeted to the center of the RF. The responses to punctate mechanical stimulation using  
203 4 or 10 g vF hairs with sufficient force to bend the hairs for 5 s were recorded.  
204 Additionally, the responses to one stroke from a camel-hair brush and a pinch stimulation  
205 from an arterial clip for 5 s were recorded. The neuronal responses to mechanical stimuli  
206 were recorded 5, 10, 20, 30, 60, and 90 min after injection by investigators blinded to  
207 group allocation (levobupivacaine, bupivacaine, or saline).

208

## 209 **Statistical analyses**

210 Prior to Experiment (1), a statistical power analysis was performed using G\*Power,  
211 version 3.1, with TDT as the primary outcome. Wallace and coworkers reported a TDT  
212 of  $3.86 \pm 0.38$  mN (mean  $\pm$  SD) at the arm [16]. Therefore, when levobupivacaine does  
213 not change TDT while bupivacaine increases TDT by 20% at the same concentration, a  
214 sample size of 6 is required for a type I error of 0.05 and power of 0.8. As we tested three  
215 doses (0.125%, 0.0625%, and 0.025%), 18 people were recruited. Mean responses in each  
216 group were first log-transformed. Results are presented as box-and-whisker plots showing  
217 the median with first and third quartiles as well as the 10th and 90th percentiles. Baseline  
218 responses were compared among groups using the Kruskal–Wallis H-test with Dunn’s  
219 post-hoc tests for multiple comparisons, while anesthesia-induced changes were  
220 compared by Mann–Whitney U-test with Bonferroni correction for multiple comparisons.  
221 The sample size calculation for Experiment (2) was based on a previous study recording  
222 changes in the firing rates of SDH neurons evoked by local anesthetics in anesthetized  
223 animals [17]. All data are presented as mean  $\pm$  SD. Baseline firing frequencies were

224 compared among groups by Kruskal–Wallis H-test with Dunn’s post-hoc tests for  
225 pairwise comparisons, while changes induced by bupivacaine and levobupivacaine were  
226 compared by Mann–Whitney U-test with Bonferroni correction. All statistical analyses  
227 were performed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA).  
228 For all statistical tests,  $P < 0.05$  (two-tailed) was considered statistically significant.  
229

## 230 **Results**

### 231 **Experiment (1): Subcutaneous injection of low-dose** 232 **bupivacaine induced greater suppression of tactile sensation** 233 **than low-dose levobupivacaine in human volunteers**

#### 234 **Patient characteristics**

235 All 18 healthy volunteers completed the study without major side effects. Demographic  
236 characteristics are summarized in Table 1.

237 **Table 1. Demographic characteristics of human volunteers**

	<b>male</b>	<b>female</b>	<b>total</b>
<b>N</b>	15	3	18
<b>Age (y.o.)</b>	33 ± 7	27 ± 4	32 ± 7
<b>Height (cm)</b>	169 ± 6	155 ± 10	167 ± 9
<b>Weight (kg)</b>	65 ± 13	45 ± 9	61 ± 15

238 Data are presented as mean ± standard deviation.

#### 239 **Carryover and period effects**

240 There were no significant differences in baseline TDT, MPT, and TPT, and no significant  
241 differences in threshold changes at 15 min post-administration between periods and  
242 anesthetics at equivalent doses (Supplementary Table S1), indicating that changes in TDT,  
243 MPT, and TPT induced by bupivacaine or levobupivacaine administration in the first  
244 period had disappeared by the start of the second period. Therefore, pooled data from the  
245 first and second periods were used to investigate the effects of levobupivacaine and  
246 bupivacaine on all outcomes.

247

### 248 **Effects of levobupivacaine and bupivacaine on sensory thresholds**

249 There were no significant differences in the TDT (Fig 3A), MPT (Fig 3B), and TPT (Fig  
250 3C) at baseline between anesthetic groups. As expected, TDT increased significantly after  
251 subcutaneous administration of both levobupivacaine and bupivacaine at concentrations  
252 of 0.125%, 0.0625%, and 0.025%. There was no significant difference in TDT between  
253 anesthetic groups at 0.125%. However, TDT was significantly higher 5 and 15 min after  
254 subcutaneous administration of 0.0625% bupivacaine compared to the same  
255 levobupivacaine concentration at 5 and 15 min post-injection ( $P = 0.029$  and  $P = 0.026$ ),  
256 and 5, 15, 30 and 45 min after administration of 0.025% bupivacaine compared to the  
257 same levobupivacaine concentration and post-administration times ( $P = 0.002$ ,  $P = 0.002$ ,  
258  $P = 0.002$ , and  $P = 0.026$ , respectively). Both levobupivacaine and bupivacaine also  
259 significantly increased the MPT at all concentrations tested as quantified by mean vF hair  
260 force, and the TPT produced by contact heat at 5 min after injection compared to before  
261 injection, without significant differences between drugs at equivalent concentrations and  
262 post-injection times (Figs 3B and 3C).

263

### 264 **Fig 3. Changes in tactile and pain thresholds in human volunteers following** 265 **subcutaneous bupivacaine and levobupivacaine injections.**

266 (A, B) Tactile detection threshold (TDT) (A) and mechanical pain threshold (MPT) (B)  
267 measured using von Frey hairs. (C) Thermal pain threshold (TPT) measured by a  
268 thermal stimulator. The TDT was significantly higher (tactile response less sensitive)  
269 following bupivacaine injection at concentrations of 0.025% and 0.0625% compared to  
270 equal-dose levobupivacaine (A), while MPT and TPT did not differ between LAs at any

271 concentrations tested (B, C). *Arrows* indicate the cutoffs (B, C), and the dotted line  
272 indicates the baseline level (A, B). \*  $P < 0.05$  between bupivacaine and  
273 levobupivacaine, #  $P < 0.05$  vs. baseline.

274

275 **Experiment (2): Subcutaneous injection of bupivacaine**  
276 **induced greater suppression of SDH neuron activity evoked by**  
277 **innocuous stimulation than equal-dose levobupivacaine in**  
278 **anesthetized rats**

279 A total of 37 neurons were identified from the T13 to L1 SDH of 37 anesthetized rats, of  
280 which 19 were classified as WDR and the remaining 18 as LT neurons. Of these, complete  
281 baseline and post-injection spike recordings were obtained from 13 WDR and 13 LT  
282 neurons for analysis. The average of depth of the electrode tip position below the dorsal  
283 spinal cord surface was  $745 \pm 103 \mu\text{m}$  for WDR neurons and  $432 \pm 70 \mu\text{m}$  for LT neurons,  
284 consistent with the known anatomic distribution.

285 **Effects of bupivacaine and levobupivacaine on WDR neuron activity**  
286 **evoked by innocuous and noxious stimuli**

287 Figs 4A and 5A show typical spike discharge patterns of WDR neurons in response to  
288 noxious stimuli (pinch and 10 g vF hair) and innocuous mechanical stimuli (brush and 4  
289 g vF hair) within corresponding receptive fields at baseline and 10, 30, and 60 min after  
290 subcutaneous administration of levobupivacaine or bupivacaine, respectively, while Figs  
291 4B and 5B show the mean changes. Both levobupivacaine and bupivacaine at 0.05%  
292 significantly inhibited the spiking responses of WDR neurons induced by noxious stimuli

293 without significant difference (Fig 4B). However, the inhibitory effects of bupivacaine  
294 on the responses of WDR neurons to (innocuous) brush and 4 g vF between 10 and 60  
295 min were significantly stronger than those of levobupivacaine (brush, 5 min  $P = 0.016$ ,  
296 10 min  $P = 0.016$ , 20 min  $P = 0.008$ , 30 min  $P = 0.008$ , 60 min  $P = 0.016$ ; 4g vF, 20 min  
297  $P = 0.032$ , 30 min  $P = 0.008$ , 60 min  $P = 0.008$ ) (Fig 5B), consistent with the effects  
298 observed on tactile thresholds in humans.

299

300 **Fig 4. Both bupivacaine and levobupivacaine strongly suppressed the spiking**  
301 **responses of wide dynamic-range neurons to noxious stimuli in anesthetized rats.**

302 (A) Typical spiking responses of wide dynamic-range (WDR) neurons to noxious  
303 stimuli (pinch and 10 g von Frey hair) at baseline and after subcutaneous administration  
304 of bupivacaine or levobupivacaine (both 0.05%). (B) Mean changes in spiking response  
305 to noxious stimuli after subcutaneous administration of bupivacaine ( $n = 5$ ),  
306 levobupivacaine ( $n = 5$ ), and saline ( $n = 3$ ).

307

308 **Fig 5. Bupivacaine suppressed the spiking response of wide-dynamic-range neurons**  
309 **to innocuous stimuli more potently than levobupivacaine in anesthetized rats.**

310 (A) Typical responses of wide-dynamic-range (WDR) neurons to innocuous stimuli  
311 (brush and 4 g von Frey hair) at baseline and after subcutaneous injection of bupivacaine  
312 and levobupivacaine (A). (B) Mean changes in spiking response after subcutaneous  
313 injection of bupivacaine ( $n = 5$ ), levobupivacaine ( $n = 5$ ), and saline ( $n = 3$ ). The  
314 suppression of firing was stronger after administration of bupivacaine. \*  $P < 0.05$   
315 between bupivacaine and levobupivacaine, #  $P < 0.05$  vs. baseline.



316

317 **Effects of bupivacaine and levobupivacaine on LT neuron activity in**  
318 **response to innocuous stimuli**

319 Fig 6A shows typical discharge patterns of LT neurons in response to innocuous  
320 mechanical stimuli (brush and 4 g vF hair) within the corresponding receptive fields at  
321 baseline and 10, 30, and 60 min after subcutaneous administration of levobupivacaine or  
322 bupivacaine, while Fig 6B shows the mean changes. The mean inhibitory effects of  
323 bupivacaine on the responses of LT neurons to brush strokes 10–30 min post-injection  
324 were significantly stronger than those of levobupivacaine ( $P = 0.016$  at 10 min,  $P = 0.008$   
325 at 20 min,  $P = 0.016$  at 30 min) (Fig 6B). Similarly, the inhibitory effects of bupivacaine  
326 on the responses of LT neurons to 4 g vF at 10 and 20 min post-injection were  
327 significantly stronger than those of levobupivacaine ( $P = 0.032$  at 10 min,  $P = 0.008$  at 20  
328 min) (Fig 6B), again consistent with the effects observed on tactile thresholds in humans.

329

330 **Fig 6. Bupivacaine suppressed the spiking response of low-threshold neurons to**  
331 **innocuous stimuli more potently than levobupivacaine in anesthetized rats.**

332 **(A)** Typical responses of low-threshold (LT) neurons to innocuous stimuli (brush and 4  
333 g von Frey hair) at baseline and after subcutaneous administration of bupivacaine and  
334 levobupivacaine. **(B)** Mean changes in spiking response after subcutaneous  
335 administration of bupivacaine ( $n = 5$ ), levobupivacaine ( $n = 5$ ), and saline ( $n = 3$ ). The  
336 suppression of firing was stronger after administration of bupivacaine. \*  $P < 0.05$   
337 between bupivacaine and levobupivacaine, #  $P < 0.05$  vs. baseline.

338

## 339 **Discussion**

340 The major findings of this study are as follows. (1) In human volunteers, both 0.125%  
341 bupivacaine and 0.125% levobupivacaine increased pain and tactile thresholds in  
342 response to vF hairs and heat stimuli, while 0.025% and 0.0625% levobupivacaine  
343 enhanced pain thresholds but not thresholds for detection of innocuous stimuli. In contrast,  
344 bupivacaine at the same low concentrations enhanced thresholds to both noxious and  
345 innocuous stimuli. In other words, low-dose bupivacaine suppressed sensation to  
346 innocuous stimuli more powerfully than levobupivacaine. (2) In extracellular in vivo  
347 recordings from rat SDH neurons, both 0.05% bupivacaine and 0.05% levobupivacaine  
348 suppressed the spiking responses to noxious stimuli (from a 10 g vF hair and clamping)  
349 with equal efficacy similarly. On the other hand, the inhibitory effects of bupivacaine on  
350 the responses of LT neurons to 4 g vF were significantly stronger than those of  
351 levobupivacaine. To our knowledge, this is the first study demonstrating that low  
352 concentrations of bupivacaine and levobupivacaine have distinct anesthetic effects in  
353 humans, with levobupivacaine suppressing nociceptive mechanical and thermal  
354 sensations as effectively as bupivacaine but preserving innocuous tactile sensation. This  
355 differential effect on sensation in humans is in accord with the distinct effects of these  
356 two LAs on the spiking responses of rat SDH neurons to innocuous and noxious stimuli.  
357 Thus, this study provides a plausible mechanism for the differential effects of bupivacaine  
358 and levobupivacaine on tactile sensation and nociception, and further suggests that low-  
359 dose levobupivacaine can suppress pain as effectively as bupivacaine but without  
360 producing a numbing sensation that may delay post-operative mobilization.

361 Sensory threshold measurements in humans revealed no significant differences

362 between bupivacaine and levobupivacaine at 0.125%, in accord with previous clinical  
363 studies reporting no significant differences in post-operative pain and motor block  
364 between bupivacaine and levobupivacaine at 0.25% and 0.5% [18, 19]. Indeed, all three  
365 of these doses are above the 95% effective dose (ED<sub>95</sub>), so no substantial differences are  
366 expected [20, 21]. At lower doses, however, levobupivacaine appears less effective than  
367 bupivacaine for blocking peripheral sensory fibers mediating tactile sensation, but  
368 roughly as effective for blocking nociceptive fibers.

369 The pricking pain sensation caused by stiff von Frey hairs is mainly transmitted by  
370 A $\delta$ -fibers [22], while the heat pain sensation is transmitted by both A $\delta$ - and C-fibers [23].  
371 The tactile sensation from softer von Frey hairs is transmitted by A $\beta$ -fibers [24]. The SDH  
372 contains neurons that respond differently to these inputs, including WDR neurons that  
373 respond to stimuli of different intensities, ranging from gentle to painful [25]. Conversely,  
374 LT neurons respond only to innocuous stimuli, mainly via A $\beta$ -fibers [26]. In the present  
375 study, 0.025% and 0.0625% levobupivacaine inhibited painful sensation but not tactile  
376 sensation in humans, while 0.05% levobupivacaine suppressed WDR neuron responses  
377 to noxious stimuli but not LT neuron responses to innocuous stimuli. These results  
378 suggest that levobupivacaine at low doses preferentially blocks A $\delta$ - and C-fiber  
379 transmission, resulting in greater relative nociceptive-specificity. Uta and colleagues also  
380 reported that L-bupivacaine (levobupivacaine) preferentially inhibited the firing of  
381 nociceptive neurons, while D-bupivacaine blocked the firing of nociceptive and non-  
382 nociceptive neurons with roughly equal efficacy as evidenced by electrophysiological  
383 analysis of rat dorsal root ganglion neurons in vitro and spinal transmission in vivo [11].

384 Levobupivacaine and bupivacaine are optical isomers with identical dissociation  
385 constants, molecular weights, and liposolubility, key factors determining the activities of

386 conventional local anesthetics [27]. Both compounds also target sodium channels.  
387 However, nine sodium channel subtypes have been identified (Nav 1.1–1.9), so  
388 differential fiber block may result from variations in channel subtype block efficacy  
389 combined with unique expression patterns among fiber types. Tetrodotoxin (TTX)-  
390 resistant Nav 1.8 and 1.9 are expressed at high levels in (nociceptive) A $\delta$ - and C-fibers  
391 [28-30], and it has been reported that levobupivacaine has a higher affinity for TTX-  
392 resistant than TTX-sensitive sodium channels. In contrast, bupivacaine has shown no  
393 difference in affinity between tetrodotoxin-sensitive and tetrodotoxin-resistant sodium  
394 channels [11, 31]. Thus, the differences in sensory block characteristics between  
395 bupivacaine and levobupivacaine may stem from differential blockade of TTX-sensitive  
396 and -resistant voltage-gated sodium channels.

397       Suppression of tactile sensation from innocuous stimuli (a brush and vF 4 g) differed  
398 between bupivacaine and levobupivacaine at 0.0625%, a concentration lower than  
399 commonly used in clinical practice [1, 32] and thus not fully investigated for sensory  
400 blocking properties. The concentration of local anesthetic decreases with distance from  
401 the injection site, so an alternative explanation for these results is that the area of tactile  
402 sensory block by levobupivacaine is smaller than that by bupivacaine at the same dose  
403 and concentration. However, the equal efficacy against nociceptive stimuli mediated by  
404 axons within the same fiber bundles suggests that this is unlikely.

405       The present study has several limitations. First, different noxious stimuli were used  
406 in human and rat experiments (thermal vs. pinch) as the thermal stimulator probe was too  
407 large for the rat hindpaw. Second, the vF hair stiffness was limited to 300 g and the heat  
408 stimulus to 47°C in human experiments to prevent skin damage, which may have also  
409 differentially influenced the analgesic effects of bupivacaine and levobupivacaine.

410 However, the recovery from levobupivacaine analgesia tended to be similar or slower  
411 than recovery from bupivacaine (Fig 3). Therefore, it is unlikely that the analgesic  
412 efficacy of levobupivacaine is inherently inferior to that of bupivacaine.

413

## 414 **Conclusion**

415 We demonstrate that low-dose levobupivacaine can preferentially block the transmission  
416 of nociceptive information without affecting the transmission of innocuous tactile  
417 information, while bupivacaine blocks both with roughly equal efficacy. Therefore,  
418 levobupivacaine may be a better choice for applications requiring pain suppression but  
419 maintenance of tactile sensation.

420

## 421 **Acknowledgments**

422 We would like to thank Dr. Masahiro Sakata (Research Planning & Drug Discovery  
423 Research, Research Laboratories, Maruho Co., LTD.) for technical assistance with the *in*  
424 *vivo* electrophysiological recordings.

425

426

## 427 **References**

- 428 1. Burlacu CL, Buggy DJ. Update on local anesthetics: focus on levobupivacaine.  
429 *Ther Clin Risk Manag.* 2008;4: 381-392. doi: [10.2147/tcrm.s1433](https://doi.org/10.2147/tcrm.s1433).
- 430 2. Dillane D, Finucane BT. Local anesthetic systemic toxicity. *Can J Anesth.*  
431 2010;57: 368-380.
- 432 3. Guinet P, Estebe JP, Ratajczak-Enselme M, Bansard JY, Chevanne F, Bec D, et  
433 al. Electrocardiographic and hemodynamic effects of intravenous infusion of bupivacaine,  
434 ropivacaine, levobupivacaine, and lidocaine in anesthetized ewes. *Reg Anesth Pain Med.*  
435 2009;34: 17-23. doi: [10.1097/AAP.0b013e31819338e2](https://doi.org/10.1097/AAP.0b013e31819338e2).
- 436 4. Tsuchiya H, Ueno T, Mizogami M. Stereostructure-based differences in the  
437 interactions of cardiotoxic local anesthetics with cholesterol-containing biomimetic  
438 membranes. *Bioorg Med Chem.* 2011;19: 3410-3415.. doi: [10.1016/j.bmc.2011.04.030](https://doi.org/10.1016/j.bmc.2011.04.030).
- 439 5. Heppolette CAA, Brunnen D, Bampoe S, Odor PM. Clinical pharmacokinetics  
440 and pharmacodynamics of levobupivacaine. *Clin Pharmacokinet.* 2020;59: 715-745. doi:  
441 [10.1007/s40262-020-00868-0](https://doi.org/10.1007/s40262-020-00868-0).
- 442 6. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, et al.  
443 Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and  
444 ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the  
445 cardiovascular system. *Anesthesiology.* 2004;101: 390-398. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-200408000-00020)  
446 [200408000-00020](https://doi.org/10.1097/00000542-200408000-00020).
- 447 7. Atiénzar MC, Palanca JM, Torres F, Borràs R, Gil S, Esteve I. A randomized  
448 comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor  
449 analgesia. *Int J Obstet Anesth.* 2008;17: 106-111.. doi: [10.1016/j.ijoa.2007.10.003](https://doi.org/10.1016/j.ijoa.2007.10.003).

- 450 8. Camorcia M, Capogna G, Berritta C, Columb MO. The relative potencies for  
451 motor block after intrathecal ropivacaine, levobupivacaine, and bupivacaine. *Anesth*  
452 *Analg.* 2007;104: 904-907. doi: [10.1213/01.ane.0000256912.54023.79](https://doi.org/10.1213/01.ane.0000256912.54023.79).
- 453 9. Lacassie HJ, Columb MO. The relative motor blocking potencies of bupivacaine  
454 and levobupivacaine in labor. *Anesth Analg.* 2003;97: 1509-1513.
- 455 10. Hakan Erbay R, Ermumcu O, Hanci V, Atalay H. A comparison of spinal  
456 anesthesia with low-dose hyperbaric levobupivacaine and hyperbaric bupivacaine for  
457 transurethral surgery: a randomized controlled trial. *Minerva Anesthesiol.* 2010;76: 992-  
458 1001.
- 459 11. Uta D, Koga K, Furue H, Imoto K, Yoshimura M. L-bupivacaine inhibition of  
460 nociceptive transmission in rat peripheral and dorsal horn neurons. *Anesthesiology.*  
461 2021;134: 88-102. doi: [10.1097/ALN.0000000000003596](https://doi.org/10.1097/ALN.0000000000003596).
- 462 12. Price DD, Dubner R, Hu JW. Trigeminothalamic neurons in nucleus caudalis  
463 responsive to tactile, thermal, and nociceptive stimulation of monkey's face. *J*  
464 *Neurophysiol.* 1976;39: 936-953. doi: [10.1152/jn.1976.39.5.936](https://doi.org/10.1152/jn.1976.39.5.936).
- 465 13. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials:  
466 part 18 of a series on evaluation of scientific publications. *Dtsch Ärztebl Int.* 2012;109:  
467 276-281. doi: [10.3238/arztebl.2012.0276](https://doi.org/10.3238/arztebl.2012.0276).
- 468 14. Zahn PK, Brennan TJ. Incision-induced changes in receptive field properties of  
469 rat dorsal horn neurons. *Anesthesiology.* 1999;91: 772-785. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-199909000-00030)  
470 [199909000-00030](https://doi.org/10.1097/00000542-199909000-00030).
- 471 15. Reali C, Fossat P, Landry M, Russo RE, Nagy F. Intrinsic membrane properties  
472 of spinal dorsal horn neurones modulate nociceptive information processing in vivo. *J*  
473 *Physiol.* 2011;589: 2733-2743.

- 474 16. Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for  
475 intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds  
476 and capsaicin-evoked hyperpathia. *Anesthesiology*. 1997;86: 1262-1272. doi:  
477 [10.1097/00000542-199706000-00006](https://doi.org/10.1097/00000542-199706000-00006).
- 478 17. Sagar DR, Kendall DA, Chapman V. Inhibition of fatty acid amide hydrolase  
479 produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. *Br J*  
480 *Pharmacol*. 2008;155: 1297-1306. doi: [10.1038/bjp.2008.335](https://doi.org/10.1038/bjp.2008.335).
- 481 18. Ilham C, Bombaci E, Yurtlu S, Çolakoğlu S. Efficiency of levobupivacaine and  
482 bupivacaine for supraclavicular block: a randomized double-blind comparative study.  
483 *Braz J Anesthesiol*. 2014;64: 177-182
- 484 19. Koch T, Fichtner A, Schwemmer U, Standl T, Volk T, Engelhard K, et al.  
485 Levobupivacaine for epidural anaesthesia and postoperative analgesia in hip surgery: a  
486 multi-center efficacy and safety equivalence study with bupivacaine and ropivacaine.  
487 *Anaesthesist*. 2008;57: 475-482. doi: [10.1007/s00101-008-1357-3](https://doi.org/10.1007/s00101-008-1357-3).
- 488 20. Bouvet L, Da-Col X, Chassard D, Daléry F, Ruynat L, Allaouchiche B, et al,  
489 editors. ED<sub>50</sub> and ED<sub>95</sub> of intrathecal levobupivacaine with opioids for Caesarean  
490 delivery. *Br J Anaesth*. 2011;106: 215-220.
- 491 21. Ginosar Y, Mirikatani E, Drover DR, Cohen SE, Riley ET. ED50 and ED95 of  
492 intrathecal hyperbaric bupivacaine coadministered with opioids for cesarean delivery.  
493 *Anesthesiology*. 2004;100: 676-682. doi: [10.1097/00000542-200403000-00031](https://doi.org/10.1097/00000542-200403000-00031).
- 494 22. Beissner F, Brandau A, Henke C, Felden L, Baumgärtner U, Treede RD, et al.  
495 Quick discrimination of A(delta) and c fiber mediated pain based on three verbal  
496 descriptors. *PLOS ONE*. 2010;5: e12944.
- 497 23. Angst MS, Tingle M, Phillips NG, Carvalho B. Determining heat and



- 498 mechanical pain threshold in inflamed skin of human subjects. *J Vis Exp.* 2009;23.
- 499 24. Ackerley R, Backlund Wasling H, Liljencrantz J, Olausson H, Johnson RD,  
500 Wessberg J. Human C-tactile afferents are tuned to the temperature of a skin-stroking  
501 caress. *J Neurosci.* 2014;34: 2879-2883. doi: [10.1523/jneurosci.2847-13.2014](https://doi.org/10.1523/jneurosci.2847-13.2014).
- 502 25. Hanai F. Effect of electrical stimulation of peripheral nerves on neuropathic pain.  
503 *Spine (Phila Pa 1976).* 2000;25: 1886-1892. doi: [10.1097/00007632-200008010-00005](https://doi.org/10.1097/00007632-200008010-00005).
- 504 26. Zimmerman A, Bai L, Ginty DD. The gentle touch receptors of mammalian skin.  
505 *Science.* 2014;346: 950-954. doi: [10.1126/science.1254229](https://doi.org/10.1126/science.1254229).
- 506 27. Vladimirov M, Nau C, Mok WM, Strichartz G. Potency of bupivacaine  
507 stereoisomers tested in vitro and in vivo: biochemical, electrophysiological, and  
508 neurobehavioral studies. *Anesthesiology.* 2000;93: 744-755. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-200009000-00024)  
509 [200009000-00024](https://doi.org/10.1097/00000542-200009000-00024).
- 510 28. Wu Y, Ma H, Zhang F, Zhang C, Zou X, Cao Z. Selective voltage-gated sodium  
511 channel peptide toxins from animal venom: pharmacological probes and analgesic drug  
512 development. *ACS Chem Neurosci.* 2018;9: 187-197.. doi:  
513 [10.1021/acchemneuro.7b00406](https://doi.org/10.1021/acchemneuro.7b00406)
- 514 29. Tsukamoto T, Chiba Y, Wakamori M, Yamada T, Tsunogae S, Cho Y, et al.  
515 Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium  
516 channel subtypes (Nav 1.1 to Nav 1.7). *Br J Pharmacol.* 2017;174: 3881-3892.. doi:  
517 [10.1111/bph.13985](https://doi.org/10.1111/bph.13985)
- 518 30. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies. *Br*  
519 *J Pharmacol.* 2018;175: 2138–2157. doi: [10.1111/bph.13962](https://doi.org/10.1111/bph.13962).
- 520 31. Oda A, Ohashi H, Komori S, Iida H, Dohi S. Characteristics of ropivacaine block  
521 of Na<sup>+</sup> channels in rat dorsal root ganglion neurons. *Anesth Analg.* 2000;91: 1213-1220.

522 doi: [10.1097/00000539-200011000-00031](https://doi.org/10.1097/00000539-200011000-00031).

523 32. Bajwa SJ, Kaur J. Clinical profile of levobupivacaine in regional anesthesia: A

524 systematic review. J Anaesthesiol Clin Pharmacol. 2013;29: 530-539. doi: [10.4103/0970-](https://doi.org/10.4103/0970-9185.119172)

525 [9185.119172](https://doi.org/10.4103/0970-9185.119172).

526

527





Figure 1

(A)



(B)





Figure 6

(A)

WDR neuron



Time after drug administration

(B)

Brush

vF 4 g




Figure 5

**(A)****WDR neuron****vF 10 g****Pinch**

Levobupivacaine

Bupivacaine

Time after drug administration

0

10

30

60



0

10

30

60

5 sec

**(B)****vF 10 g****Pinch**%change of discharge  
frequency of WDR  
neurons (%)%change of discharge  
frequency of WDR  
neurons (%)

● Bupivacaine ● Levobupivacaine ● Saline

Figure 4




Figure 3




Figure 2